瘢痕疙瘩切除后病灶内注射5-氟尿嘧啶的疗效及基因表达分析
本研究分析瘢痕疙瘩对5-氟尿嘧啶(5-FU)治疗的反应及长期预防复发效果。瘢痕疙瘩切除后病灶内注射5-FU可预防复发2年且无不良事件报告。通过对同一瘢痕疙瘩治疗与未治疗活检标本的微阵列数据进行随机森林分析,作者构建了5-FU治疗瘢痕疙瘩的基因表达谱,发现YAP1和CCL-2等基因表达变化可预测治疗状态,并首次描述瘢痕疙瘩异质性。
要点
- 瘢痕疙瘩切除后病灶内注射5-FU可预防复发2年,无不良事件报告。
- 随机森林分析微阵列数据提高了统计效力,构建了5-FU治疗瘢痕疙瘩的基因表达谱。
- YAP1和CCL-2等基因表达变化可预测5-FU治疗状态,部分基因功能未知。
核心结论
- 瘢痕疙瘩切除后病灶内注射5-FU可预防复发2年,无不良事件报告。
- 5-FU治疗瘢痕疙瘩的基因表达谱包含YAP1和CCL-2等基因,其表达变化可预测治疗状态。
- 多维分析微阵列结果首次描述了瘢痕疙瘩异质性。
研究设计与样本
- 研究类型为治疗性研究,证据等级V。
- 分析同一瘢痕疙瘩治疗与未治疗活检标本的基因表达。
- 采用随机森林分析微阵列数据。
主要发现
- 瘢痕疙瘩切除后病灶内注射5-FU预防复发2年,无不良事件报告。
- 随机森林分析提高了统计效力,得以无假设地构建5-FU治疗瘢痕疙瘩的基因表达谱。
- 发现YAP1和CCL-2等基因表达变化可预测5-FU治疗状态,部分基因此前未与瘢痕疙瘩生物学关联且功能未知。
- 首次通过多维分析微阵列结果描述瘢痕疙瘩异质性。
临床怎么用
- 瘢痕疙瘩切除后病灶内注射5-FU可作为预防复发的治疗选择,需注意证据等级为V。
- YAP1和CCL-2等基因表达变化或可作为预测5-FU治疗状态的分子标志物。
- 研究方法和工具可能有助于克服瘢痕疙瘩研究中的挑战并开发有效治疗。
局限性
- 瘢痕疙瘩缺乏动物或体外模型,难以验证治疗组织样本或细胞的数据并开发靶向治疗。
- 证据等级为V。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Keloids are benign fibroproliferative skin tumors that can cause disfigurement and disability. Although they frequently recur after excision or medical management and can affect 6 to 16 percent of African Americans, there is no gold standard therapy. Keloids are challenging to study because there are no animal or in vitro models of this disorder. This makes it very difficult to validate data from treated tissue samples or cells and develop targeted therapies for this disease. In this study, the authors demonstrate that intralesional 5-fluorouracil injection after keloid excision prevents recurrence for 2 years, with no reported adverse events. The authors analyze the expression of treated and untreated biopsy specimens of the same keloids in their native context to capture insights that may be missed by in vitro cell culture models and correct for intrakeloid variability. Random forest analysis of the microarray data dramatically increased the statistical power of the authors' results, permitting hypothesis-free creation of a gene expression profile of 5-fluorouracil-treated keloids. Through this analysis, the authors found a set of genes, including YAP1 and CCL-2, whose expression changes predict 5-fluorouracil therapy status and include genes that have not previously been associated with keloid biology and are of unknown function. The authors further describe keloid heterogeneity for the first time using multidimensional analysis of their microarray results. The methods and tools the authors developed in this research may overcome some of the challenges in studying keloids and developing effective treatments for this disease. CLINICAL QUESTION/LEVEL OF EVIDENCE:: Therapeutic, V.
引用
- LaRanger R, Karimpour-Fard A, Costa C, et al. Analysis of Keloid Response to 5-Fluorouracil Treatment and Long-Term Prevention of Keloid Recurrence. Plast Reconstr Surg. 2019. PMID: 30531622. doi:10.1097/PRS.0000000000005257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。